Intellectual Property India Publishes Patent Application for 'Antisense Oligomers For Treatment Of Non-Sense Mediated Rna Decay Based Conditions And Diseases' Filed by Stoke Therapeutics, Inc.

MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202517047030 A) filed by Stoke Therapeutics, Inc., Bedford, U.S.A., on May 15, for 'antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases.'

Inventor(s) include Aznarez, Isabel; Kach, Jacob; Ramachandran, Pavitra; and Saiz, Ana Corrionero.

The application for the patent was published on Aug. 22, under issue no. 34/2025.

According to the abstract released by the Intellectual Property India: "Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant or reduced protein expression, and therapeutic agents which can target the alternative splicing events in the genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency."

The patent application was internationally filed on Oct. 30, 2023, under International application No.PCT/US2023/036297.

Disclaimer: Curated by HT Syndication.